TOKYO, Mar 10 (Pulse News Wire) – Nichiban CO.,LTD. (4218.T) reported that its parent company, Daiho Pharmaceutical Co., Ltd., finalized its fiscal year 2025 earnings.
As of December 31, 2025, Daiho Pharmaceutical had operating profit of ¥44.785 billion, ordinary profit of ¥44.758 billion, and net profit of ¥33.557 billion. Revenue was recorded at ¥215.621 billion. Daiho Pharmaceutical holds 33.22% of NichiBan’s voting rights as of September 30, 2025.
The capital structure includes a capital stock of ¥200 million and retained earnings totaling ¥411.979 billion. Key shareholders include Otsuka Corporation, which owns 100% of the shares. In addition, the company disclosed its board members and their roles, highlighting President and CEO Koji Kobayashi and other key executives overseeing various departments such as human resources, intellectual property, legal affairs, finance, and pharmaceutical technology.
🟡 Confidence: Standard AI-translated content.